1.中山大学附属第一医院神经科,广东 广州 510080
2.复旦大学附属中山医院神经内科,上海 200032
3.深圳市第二人民医院神经内科,广东 深圳 518035
林丽山,学士,硕士生,研究方向:神经退行性疾病的临床与基础研究,E-mail:linlsh6@mail2.sysu.edu.cn
苏凤娟,共同第一作者,学士,护理师,研究方向:神经退行性疾病的临床研究,E-mail:jisufengjuan@163.com;
收稿:2021-07-12,
纸质出版:2021-11-20
移动端阅览
林丽山,苏凤娟,吴腾腾等.中国南方地区亨廷顿患者不同运动分型的临床特征[J].中山大学学报(医学科学版),2021,42(06):944-949.
LIN Li-shan,SU Feng-juan,WU Teng-teng,et al.Clinical Characteristics of Different Motor Phenotypes in Patients with Huntington’s Disease in Southern China[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(06):944-949.
林丽山,苏凤娟,吴腾腾等.中国南方地区亨廷顿患者不同运动分型的临床特征[J].中山大学学报(医学科学版),2021,42(06):944-949. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0618.
LIN Li-shan,SU Feng-juan,WU Teng-teng,et al.Clinical Characteristics of Different Motor Phenotypes in Patients with Huntington’s Disease in Southern China[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(06):944-949. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0618.
目的
2
探讨中国南方地区亨廷顿病患者不同运动分型的临床特征,便于个体化精准治疗。
方法
2
纳入自2014年3月至2021年5月在中国亨廷顿病协作网广州中心登记的亨廷顿病患者58例,利用亨廷顿舞蹈症整体评估量表对患者进行运动分型,精神状态、认知功能以及全面生活能力测试,最后利用Kruskal-Wallis
H
检验方法对不同分型患者各组临床特征进行分析。
结果
2
中国南方地区亨廷顿患者运动分型以混合型为主,共42例,占比72.41%。不同分型临床特征不同,运动机能减退-僵硬为主型患者全面生活能力低于舞蹈症状为主型患者[8.00(4.00
~
11.00)
vs
13.00(11.00
~
13.00);
P
=0.037]。
结论
2
中国南方地区亨廷顿患者运动症状复杂。精准的运动分型,对药物治疗与预后评估有一定的意义。
Objective
2
To explore clinical characteristics of different motor phenotypes in patients with Huntington’s disease in southern China for individualized precise treatment.
Method
2
A total of 58 Huntington’s disease (HD) patients were enrolled from Guangzhou Center of Chinese Huntington’s Disease Network (CHDN) from March 2014 to May 2021. United Huntington’s Disease Rating Scale (UHDRS) was used to assess patients’ motor function, mental state, cognition and total functional capacity (TFC). The differences of clinical characteristics among different motor phenotypes were analyzed by Kruskal-Wallis test.
Results
2
In southern China, HD patients showed a predominant mixed-motor phenotype, with 72.41% (42/58) of all cases. The clinical characteristics among different motor phenotypes were different, and the TFC score in hypokinetic-rigidity phenotype was lower than that in choreatic motor phenotype [8.00 (4.00~11.00)
vs
13.00 (11.00~13.00),
P
=0.037].
Conclusion
2
The symptoms of movement disorders in HD patients in southern China are complex. The precise classification of motor phenotype is helpful for the treatment and prognosis of HD.
Pringsheim T , Wiltshire K , Day L , et al . The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis [J]. Mov Disord , 2012 , 27 ( 9 ): 1083 - 1091 .
Ross CA , Aylward EH , Wild EJ , et al . Huntington disease: natural history, biomarkers and prospects for therapeutics [J]. Nat Rev Neurol , 2014 , 10 ( 4 ): 204 - 216 .
Bachoud-Lévi A , Ferreira J , Massart R , et al . International guidelines for the treatment of Huntington's disease [J]. Front Neurol , 2019 , 10 : 710 .
Frank S , Testa CM , Stamler D , et al . Effect of deutetrabenazine on chorea among patients with Huntington disease [J]. JAMA , 2016 , 316 ( 1 ): 40 - 50 .
翁加俊 , 于文娟 , 李华芳 . 单胺类囊泡转运体2抑制剂治疗迟发性运动障碍研究进展 [J]. 中国神经精神疾病杂志 , 2018 , 44 ( 2 ): 125 - 128 .
Weng JJ , Yu WJ , Li HF . Research progress of monoamine vesicle transporter 2 inhibitors in the treatment of tardive dyskinesia [J]. Chin J Nerv Ment Dis , 2018 , 44 ( 2 ): 125 - 128 .
Unified Huntington's Disease Rating Scale : reliability and consistency . Huntington Study Group [J]. Mov Disord , 1996 , 11 ( 2 ): 136 - 142 .
Zhang Y , Long JD , Mills JA , et al . Indexing disease progression at study entry with individuals at-risk for Huntington disease [J]. Am J Med Genet B Neuropsychiatr Genet , 2011 , 156 ( 7 ): 751 - 763 .
Hart EP , Marinus J , Burgunder J , et al . Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease [J]. Mov Disord , 2013 , 28 ( 8 ): 1142 - 1145 .
Julayanont P , Heilman KM , Mcfarland NR . Early-motor phenotype relates to neuropsychiatric and cognitive disorders in Huntington's disease [J]. Mov Disord , 2020 , 35 ( 5 ): 781 - 788 .
Achenbach J , Hein SM , Saft C . Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington's disease [J]. Brain Behav , 2020 , 10 ( 8 ): e01704 .
Carlozzi NE , Schilling SG , Boileau NR , et al . How different aspects of motor dysfunction influence day-to-day function in huntington's disease [J]. Mov Disord , 2019 , 34 ( 12 ): 1910 - 1914 .
Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson's disease and Huntington's disease: a review [J]. Curr Neuropharmacol , 2019 , 17 ( 2 ): 165 - 175 .
Tabrizi SJ , Leavitt BR , Landwehrmeyer GB , et al . Targeting huntingtin expression in patients with Huntington's disease [J]. N Engl J Med , 2019 , 380 ( 24 ): 2307 - 2316 .
HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network . A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease [J]. JAMA Neurol , 2013 , 70 ( 1 ): 25 - 33 .
Rodrigues FB , Wild EJ . Huntington's disease clinical trials corner: April 2020 [J]. J Huntingtons Dis , 2020 , 9 ( 2 ): 185 - 197 .
Jacobs M , Hart EP , van Zwet EW , et al . Progression of motor subtypes in Huntington's disease: a 6-year follow-up study [J]. J Neurol , 2016 , 263 ( 10 ): 2080 - 2085 .
Tabrizi SJP , Scahill RIP , Owen GP , et al . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data [J]. Lancet Neurol , 2013 , 12 ( 7 ): 637 - 649 .
Foltynie T , Brayne C , Barker RA . The heterogeneity of idiopathic Parkinson's disease [J]. J Neurol , 2002 , 249 ( 2 ): 138 - 145 .
0
浏览量
425
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
